---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-028484"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:51:05.580817+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# uniQure reports $308.5M net loss in FY2023; cash $617.9M; pipeline programs advancing

## Summary
- Net loss $308.5M ($6.47 per share) vs $126.8M ($2.71) in FY2022; revenue $15.8M vs $106.5M.
- Cash and investments $617.9M as of Dec 31, 2023; expects to fund operations into Q2 2027.
- Strategic reorganization expected to deliver $180M in cost savings over three years.
- FDA clearance received for IND applications for AMT-260 (mTLE) and AMT-191 (Fabry); enrollment in Phase I/II trials expected H1 2024.
- Regulatory interactions for AMT-130 (Huntington's) approval pathway expected in 2024; interim data update in mid-2024.

## SEC filing metadata
- accession: 0001104659-24-028484
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/0001104659-24-028484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/tm246858d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-028484
- JSON: https://secwatch.observer/filing/0001104659-24-028484.json
- Plain text: https://secwatch.observer/filing/0001104659-24-028484.txt

## Key facts
- Earnings Releases
  uniQure N.V. reported fourth quarter and full year 2023 results: revenue $15.8 million.
  - Period: fourth quarter and full year 2023
  - Revenue: $15.8 million
  - Result: reported results
  source text: Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2027. Revenues: Revenue for the year ended December 31, 2023 was $15.8 million, compared to $106.5 million in the same period in 2022. Revenues in 2022 included $100.0 million of license revenue related to the U.S. first sale milestone payment of HEMGENIX ®
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465924028484/0001104659-24-028484-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.